

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1.-10. (Canceled)

11. (Previously Presented) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising administering to said animal a composition comprising: a therapeutically-effective amount of a first active ingredient selected from the group consisting of avermectin, 22,23-dihydroavermectin B<sub>1</sub>, and milbemycin; and, a therapeutically-effective amount of a second active ingredient selected from the group consisting of agonists and antagonists of the nicotinic acetylcholine receptors of insects.

12. (Previously Presented) The method according to claim 11 wherein said first active ingredient comprises an avermectin, a milbemycin, or both, and said second active ingredient comprises a chloronicotinyl, a chlorothiazolyl, or both.

13. (Previously Presented) The method according to claim 11 wherein said first active ingredient comprises moxidectin.

14. (Previously Presented) The method according to claim 13 wherein said second active ingredient comprises imidacloprid.

15. (Previously Presented) The method according to claim 11 wherein said first active ingredient comprises ivermectin.

16. (Previously Presented) The method according to claim 15 wherein said second active ingredient comprises imidacloprid.

17. (Previously Presented) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising:

identifying an animal having both an endoparasitic infection and an ectoparasitic infection; and,

administering to said identified animal a composition comprising

a therapeutically-effective amount of a first active ingredient selected from the group consisting of avermectin, 22,23-dihydroavermectin B<sub>1</sub>, and milbemycin; and,

a therapeutically-effective amount of a second active ingredient selected from the group consisting of agonists and antagonists of the nicotinerbic acetylcholine receptors of insects.

18. (Previously Presented) The method according to claim 17 wherein said first active ingredient comprises an avermectin, a milbemycin, or both, and said second active ingredient comprises a chloronicotinyl, a chlorothiazolyl, or both.

19. (Previously Presented) The method according to claim 17 wherein said first active ingredient comprises moxideetin.

20. (Previously Presented) The method according to claim 19 wherein said second active ingredient comprises imidacloprid.

21. (Previously Presented) The method according to claim 17 wherein said first active ingredient comprises ivermectin.

22. (Previously Presented) The method according to claim 21 wherein said second active ingredient comprises imidacloprid.

23. (New) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising administering to said animal a composition comprising: a therapeutically-effective amount of moxideetin; and, a therapeutically-effective amount of imidacloprid.

24. (New) A method for treating an animal having both an endoparasitic infection and an ectoparasitic infection comprising:

identifying an animal having both an endoparasitic infection and an ectoparasitic infection; and,

administering to said identified animal a composition comprising

**DOCKET NO.:** Le A 31 923 C2 (BAYE-0050)

**PATENT**

**Application No.:** 10/613,819

**Office Action Dated:** June 19, 2009

a therapeutically-effective amount of moxidectin; and,  
a therapeutically-effective amount of imidacloprid.